

Special Issue

Cell Therapy for Cancers

Message from the Guest Editor

Cell therapy is part of the therapeutic arsenal of cancer treatment and has become a major therapeutic option in hematology, with the transplant of hematopoietic stem cells. It is now taking a new turn due to better knowledge of the functioning of immune cells and has benefited from renewed interest with the development of CAR T cells. Since their arrival on the market, other cells have entered the race, including CAR NK cells, CAR macrophages or CAR T regs, all with their own advantages and inconveniences. In this Special Issue, we wish to take stock of the developing and available cell therapies indicated in the treatment of hemopathies and solid tumors. We will discuss their regulatory status, their method of development and the criteria for evaluating their efficacy in vitro and in vivo. Dr. Véronique Décot

Guest Editor

Dr. Veronique Decot

CHRU de Nancy, Unité de Thérapie Cellulaire Etbanque de Tissus,
54500 Vandoeuvre-lès-Nancy, France

Deadline for manuscript submissions

closed (20 April 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/85871

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)